Galectin Therapeutics (GALT) Treasury Shares (2010 - 2026)

Galectin Therapeutics' Treasury Shares history runs 17 years deep, the most recent figure standing at $4.2 million for Q1 2026.

• In Q1 2026, Treasury Shares fell 56.52% year-over-year to $4.2 million; the TTM figure through Mar 2026 stood at $4.2 million (down 56.52% YoY), while the FY2025 annual figure was $4.2 million, down 56.52% from the prior year.
• Treasury Shares was $4.2 million for Q1 2026 at Galectin Therapeutics, roughly flat from $4.2 million in the prior quarter.
• In the past five years, Treasury Shares ranged from a high of $12.0 million in Q2 2023 to a low of $4.0 million in Q3 2025.
• Historically, Treasury Shares has averaged $9.2 million across 5 years, with a median of $9.6 million in 2024.
• The sharpest annual moves came in 2023 and 2025: Treasury Shares gained 10.13% in 2023, then tumbled 58.72% in 2025.
• A 5-year view of Treasury Shares shows it stood at $11.6 million in 2022, then fell by 19.91% to $9.3 million in 2023, then advanced by 3.67% to $9.6 million in 2024, then tumbled by 56.52% to $4.2 million in 2025, then changed by 0.0% to $4.2 million in 2026.
• The last three Treasury Shares figures came in at $4.2 million (Q1 2026), $4.2 million (Q4 2025), and $4.0 million (Q3 2025), per Business Quant data.